Research map: Phase 3 Trial of Weekly Oral Islatravir–Lenacapavir for HIV-1 Treatment

Back to the article

Papers in this map

  1. Mobile phone technologies improve adherence to antiretroviral treatment in a resource-limited setting: a randomized controlled trial of text message reminders · Cristian Pop-Eleches · 2011 · 1031 citations · Cited by this paper
  2. Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial · Amy E. Colson · 2026 · 2 citations · Cites this paper
  3. Health Care–Associated Infections in U.S. Hospitals, 2023 versus 2015 · 2026 · Related
  4. Clinical targeting of HIV capsid protein with a long-acting small molecule · John O. Link · 2020 · 448 citations · Cited by this paper
  5. Once-weekly oral antiretroviral therapy for HIV · María del Mar Arcos-Rueda · 2026 · Cites this paper
  6. Mineralocorticoid Receptor Antagonism — FINDing Another Benefit · 2026 · Related
  7. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials · Jean Bisimwa Nachega · 2014 · 359 citations · Cited by this paper
  8. HIV immune activity persists in some South African teenagers despite viral suppression · Paul Adepoju · 2026 · Cites this paper
  9. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer · 2026 · Related
  10. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection · Sorana Segal‐Maurer · 2022 · 331 citations · Cited by this paper
  11. L'activité immunitaire du VIH persiste chez certains adolescents sud-africains malgré la suppression virale · Paul Adepoju · 2026 · Cites this paper
  12. Time to Stop? Rethinking the Duration of Maintenance Treatment in Multiple Myeloma · 2026 · Related
  13. A systematic review of treatment fatigue among HIV-infected patients prescribed antiretroviral therapy · Kasey Claborn · 2014 · 172 citations · Cited by this paper
  14. Transdermal Estradiol Patches in Prostate Cancer · 2026 · Related
  15. Long-acting antiretrovirals and HIV treatment adherence · Jean Bisimwa Nachega · 2023 · 145 citations · Cited by this paper
  16. Left Ventricular Unloading in High-Risk PCI · 2026 · Related
  17. Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: an open-label, phase 1b, consecutive-panel trial · Dirk Schürmann · 2020 · 98 citations · Cited by this paper
  18. Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma · 2026 · Related
  19. Current ART, determinants for virologic failure and implications for HIV drug resistance: an umbrella review · SeyedAhmad SeyedAlinaghi · 2023 · 92 citations · Cited by this paper
  20. Koebner Phenomenon from Wet Cupping · 2026 · Related
  21. The Acceptability and Perceived Usefulness of a Weekly Clinical SMS Program to Promote HIV Antiretroviral Medication Adherence in KwaZulu-Natal, South Africa · Nathan Georgette · 2016 · 59 citations · Cited by this paper
  22. More on Digital Twin–Guided Ablation for Ventricular Tachycardia · 2026 · Related
  23. Advances in long-acting slow effective release antiretroviral therapies for treatment and prevention of HIV infection · Mohammad Ullah Nayan · 2023 · 53 citations · Cited by this paper
  24. Cross-Correction in HSC Gene Therapy for Metachromatic Leukodystrophy · 2026 · Related
  25. Safety, tolerability, and pharmacokinetics of single‐ and multiple‐dose administration of islatravir (MK‐8591) in adults without HIV · Randolph P. Matthews · 2021 · 50 citations · Cited by this paper
  26. Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, randomised, controlled, double-blind, non-inferiority trial · Anthony Mills · 2024 · 35 citations · Cited by this paper
  27. U.S. patient preferences for long‐acting HIV treatment: a discrete choice experiment · Susan Marie Graham · 2023 · 32 citations · Cited by this paper
  28. Association of ART regimen and adherence to viral suppression: an observational study of a clinical population of people with HIV · Jasmine A. Manalel · 2024 · 28 citations · Cited by this paper
  29. Long-Acting Injectable Therapy for People with HIV: Looking Ahead with Lessons from Psychiatry and Addiction Medicine · Gabriel G. Edwards · 2022 · 21 citations · Cited by this paper
  30. Who Wants to Switch? Gauging Patient Interest in Novel Antiretroviral Therapies · Caroline Derrick · 2018 · 18 citations · Cited by this paper
  31. Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial · Jürgen Kurt Rockstroh · 2025 · 17 citations · Cited by this paper
  32. Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 · Amy E. Colson · 2025 · 16 citations · Cited by this paper
  33. Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions · Anna María Geretti · 2025 · 13 citations · Cited by this paper
  34. No antagonism or cross-resistance and a high barrier to the emergence of resistance in vitro for the combination of islatravir and lenacapavir · Tracy L. Diamond · 2024 · 12 citations · Cited by this paper
  35. Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy · Jacob Stout · 2024 · 8 citations · Cited by this paper
  36. Three-Year Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as a Switch Strategy in the Real World · Alejandro de Gea Grela · 2025 · 8 citations · Cited by this paper
  37. Oral antiretroviral adherence interventions in the era of U=U · Claire Keene · 2025 · 8 citations · Cited by this paper

Source: OpenAlex (CC0)